Little excitement over Merck's C-SURFER HCV trial data
This article was originally published in Scrip
Executive Summary
After 12 weeks of treatment with Merck's once-daily treatment regimen of 100mg of grazoprevir, a NS3/4A protease inhibitor, and 50mg of elbasvir, 99% of patients with advanced chronic kidney disease (CKD) with chronic hepatitis C virus (HCV) genotype 1 (GT1) in the prespecified primary population for analysis of efficacy data achieved a sustained virologic response 12 weeks after the completion of treatment (SVR12).